FXR Agonist Compounds for NAFLD and NASH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) lack effective therapeutic options, particularly novel FXR agonists that can address liver fibrosis and metabolic disorders effectively.
Innovation Solution
Development of specific compounds, such as those represented by Formula (II), which act as FXR agonists or in combination with TR-β agonists, to administer therapeutically effective amounts to reduce liver fat content, fibrosis, and ameliorate fatty liver diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FXR agonist compounds are administered to treat NAFLD and NASH, then liver fat content and fibrosis are reduced, but the lack of effective therapeutic options limits treatment efficacy
Solution Approach 1:
The patent segments the therapeutic approach by identifying and developing multiple distinct FXR agonist compounds with different chemical structures (Formula I, II, III, IV, V) and mechanisms of action. This segmentation provides diverse therapeutic options while maintaining reliable treatment efficacy through multiple compound candidates targeting the same FXR pathway.
Solution Approach 2:
The patent applies parameter changes by modifying chemical parameters of FXR agonist compounds (substituent groups R1-R6, molecular weight, lipophilicity) to optimize both treatment efficacy and therapeutic versatility. This allows generation of compound libraries with varied potencies and profiles to address different aspects of NAFLD and NASH pathology.
2Reliability
If novel FXR agonist compounds are developed to address liver fibrosis and metabolic disorders, then treatment effectiveness improves, but the complexity of compound development increases
Solution Approach 1:
The patent achieves universality by designing FXR agonist compounds that simultaneously address multiple pathological features of NAFLD and NASH including liver fat accumulation, fibrosis, and metabolic disorders through a single therapeutic mechanism. This multi-functionality improves treatment effectiveness while reducing the need for multiple separate drug developments.
Solution Approach 2:
The patent uses FXR (farnesoid X receptor) as an intermediary target that mediates the therapeutic effects of the developed compounds. By targeting this central intermediary, the compounds can indirectly regulate multiple downstream pathways involved in lipid metabolism, inflammation, and fibrosis, simplifying the development process while maintaining effectiveness.
3Productivity
If compounds are administered to reduce liver fat and fibrosis, then metabolic disorders are ameliorated, but the absence of effective current treatments limits clinical applicability
Solution Approach 1:
The patent enables self-service by designing FXR agonist compounds that activate endogenous metabolic pathways through the FXR receptor, allowing the body's own metabolic systems to regulate liver fat and fibrosis without requiring external continuous intervention. This improves productivity of metabolic improvement while enhancing reliability of clinical applicability through physiological self-regulation.
Data Source
AI summary
The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.